Cargando…
Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis
BACKGROUND: In patients treated with dimethyl fumarate, absolute lymphocyte count decline typically occurs during the first year and then plateaus; early drops have been associated with the development of severe prolonged lymphopenia. OBJECTIVE: We investigated the effect of dimethyl fumarate on abs...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227148/ https://www.ncbi.nlm.nih.gov/pubmed/32440353 http://dx.doi.org/10.1177/2055217320918619 |
_version_ | 1783534441855975424 |
---|---|
author | Buckle, Guy Bandari, Daniel Greenstein, Jeffrey Gudesblatt, Mark Khatri, Bhupendra Kita, Mariko Repovic, Pavle Riser, Emily Weinstock-Guttman, Bianca Thrower, Ben Loring, Sherrill Riester, Katherine Everage, Nick Prada, Claudia Koulinska, Irene Mann, Monica |
author_facet | Buckle, Guy Bandari, Daniel Greenstein, Jeffrey Gudesblatt, Mark Khatri, Bhupendra Kita, Mariko Repovic, Pavle Riser, Emily Weinstock-Guttman, Bianca Thrower, Ben Loring, Sherrill Riester, Katherine Everage, Nick Prada, Claudia Koulinska, Irene Mann, Monica |
author_sort | Buckle, Guy |
collection | PubMed |
description | BACKGROUND: In patients treated with dimethyl fumarate, absolute lymphocyte count decline typically occurs during the first year and then plateaus; early drops have been associated with the development of severe prolonged lymphopenia. OBJECTIVE: We investigated the effect of dimethyl fumarate on absolute lymphocyte counts and CD4+/CD8+ T cells in patients with relapsing–remitting multiple sclerosis treated with dimethyl fumarate in routine practice. METHODS: Lymphocyte data were collected via medical chart abstraction. Primary endpoint: change from baseline in absolute lymphocyte count and CD4+/CD8+ counts at 6‐month intervals following dimethyl fumarate initiation. RESULTS: Charts of 483 patients were abstracted and 476 patients included in the analysis. Mean baseline absolute lymphocyte count (2.23 × 10(9)/l) decreased by ∼39% (95% confidence interval: –41.1 to –37.2) by month 6 and 44% (95% confidence interval: –46.6 to –42.1) by month 12. CD4+ and CD8+ T-cell subsets strongly correlated with absolute lymphocyte count, with greater decreases from baseline to 6 months vs 6–12 months, and in CD8+ vs CD4+ T cells. Prior natalizumab was not a risk factor for lymphopenia. CONCLUSION: Dimethyl fumarate-associated decline in absolute lymphocyte count in the first 12 months correlated with decline in CD4+ and CD8+ T cells and was independent of prior natalizumab. Absolute lymphocyte count monitoring continues to be an effective strategy to identify patients at risk of prolonged lymphopenia. |
format | Online Article Text |
id | pubmed-7227148 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-72271482020-05-21 Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis Buckle, Guy Bandari, Daniel Greenstein, Jeffrey Gudesblatt, Mark Khatri, Bhupendra Kita, Mariko Repovic, Pavle Riser, Emily Weinstock-Guttman, Bianca Thrower, Ben Loring, Sherrill Riester, Katherine Everage, Nick Prada, Claudia Koulinska, Irene Mann, Monica Mult Scler J Exp Transl Clin Original Research Paper BACKGROUND: In patients treated with dimethyl fumarate, absolute lymphocyte count decline typically occurs during the first year and then plateaus; early drops have been associated with the development of severe prolonged lymphopenia. OBJECTIVE: We investigated the effect of dimethyl fumarate on absolute lymphocyte counts and CD4+/CD8+ T cells in patients with relapsing–remitting multiple sclerosis treated with dimethyl fumarate in routine practice. METHODS: Lymphocyte data were collected via medical chart abstraction. Primary endpoint: change from baseline in absolute lymphocyte count and CD4+/CD8+ counts at 6‐month intervals following dimethyl fumarate initiation. RESULTS: Charts of 483 patients were abstracted and 476 patients included in the analysis. Mean baseline absolute lymphocyte count (2.23 × 10(9)/l) decreased by ∼39% (95% confidence interval: –41.1 to –37.2) by month 6 and 44% (95% confidence interval: –46.6 to –42.1) by month 12. CD4+ and CD8+ T-cell subsets strongly correlated with absolute lymphocyte count, with greater decreases from baseline to 6 months vs 6–12 months, and in CD8+ vs CD4+ T cells. Prior natalizumab was not a risk factor for lymphopenia. CONCLUSION: Dimethyl fumarate-associated decline in absolute lymphocyte count in the first 12 months correlated with decline in CD4+ and CD8+ T cells and was independent of prior natalizumab. Absolute lymphocyte count monitoring continues to be an effective strategy to identify patients at risk of prolonged lymphopenia. SAGE Publications 2020-04-29 /pmc/articles/PMC7227148/ /pubmed/32440353 http://dx.doi.org/10.1177/2055217320918619 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Paper Buckle, Guy Bandari, Daniel Greenstein, Jeffrey Gudesblatt, Mark Khatri, Bhupendra Kita, Mariko Repovic, Pavle Riser, Emily Weinstock-Guttman, Bianca Thrower, Ben Loring, Sherrill Riester, Katherine Everage, Nick Prada, Claudia Koulinska, Irene Mann, Monica Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis |
title | Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis |
title_full | Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis |
title_fullStr | Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis |
title_full_unstemmed | Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis |
title_short | Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis |
title_sort | effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis |
topic | Original Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227148/ https://www.ncbi.nlm.nih.gov/pubmed/32440353 http://dx.doi.org/10.1177/2055217320918619 |
work_keys_str_mv | AT buckleguy effectofdimethylfumarateonlymphocytesubsetsinpatientswithrelapsingmultiplesclerosis AT bandaridaniel effectofdimethylfumarateonlymphocytesubsetsinpatientswithrelapsingmultiplesclerosis AT greensteinjeffrey effectofdimethylfumarateonlymphocytesubsetsinpatientswithrelapsingmultiplesclerosis AT gudesblattmark effectofdimethylfumarateonlymphocytesubsetsinpatientswithrelapsingmultiplesclerosis AT khatribhupendra effectofdimethylfumarateonlymphocytesubsetsinpatientswithrelapsingmultiplesclerosis AT kitamariko effectofdimethylfumarateonlymphocytesubsetsinpatientswithrelapsingmultiplesclerosis AT repovicpavle effectofdimethylfumarateonlymphocytesubsetsinpatientswithrelapsingmultiplesclerosis AT riseremily effectofdimethylfumarateonlymphocytesubsetsinpatientswithrelapsingmultiplesclerosis AT weinstockguttmanbianca effectofdimethylfumarateonlymphocytesubsetsinpatientswithrelapsingmultiplesclerosis AT throwerben effectofdimethylfumarateonlymphocytesubsetsinpatientswithrelapsingmultiplesclerosis AT loringsherrill effectofdimethylfumarateonlymphocytesubsetsinpatientswithrelapsingmultiplesclerosis AT riesterkatherine effectofdimethylfumarateonlymphocytesubsetsinpatientswithrelapsingmultiplesclerosis AT everagenick effectofdimethylfumarateonlymphocytesubsetsinpatientswithrelapsingmultiplesclerosis AT pradaclaudia effectofdimethylfumarateonlymphocytesubsetsinpatientswithrelapsingmultiplesclerosis AT koulinskairene effectofdimethylfumarateonlymphocytesubsetsinpatientswithrelapsingmultiplesclerosis AT mannmonica effectofdimethylfumarateonlymphocytesubsetsinpatientswithrelapsingmultiplesclerosis |